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Abstract: Atherosclerosis is a leading cause of coronary heart disease and stroke. Since 1981, 
more than 980,000 cases of AIDS have been reported in the United States. According to the 
Centers for Disease Control, more than 1 million Americans may be infected with HIV . By 
killing or damaging CD4+ T cells of the body’s immune system, HIV progressively destroys the 
body’s ability to fight infections. People diagnosed with AIDS often suffer from life-threatening 
diseases caused by opportunistic infections such as tuberculosis. HIV-infected individuals have 
increased risks for atherosclerosis. This review summarizes the effects of oxidized low density 
lipoproteins in impairing macrophage functions in individuals with atherosclerosis (with and 
without HIV infection) thereby enhancing the susceptibility to Mycobacterium tuberculosis 
infection.
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Introduction
Oxidized low-density lipoprotein (ox-LDL) has been shown in several studies to be 
an independent marker of the progression of atherosclerosis.1–4 The   pathophysiology 
relates to macrophage ingestion of excess ox-LDL and the formation of foam cells, 
the acknowledged trigger of atherosclerosis.5 It has been shown that both high-
density   lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol contain 
the   antioxidant enzyme glutathione peroxidase embedded in the lipoprotein, and a 
  continuous supply of glutathione (GSH) is needed to prevent the oxidation of HDL and 
LDL cholesterol.6 The observation that excessive ox-LDL ingestion by   macrophage 
interferes with normal macrophage function may have implications in other disease 
conditions in which low GSH plays a role, such as HIV infection. Individuals with 
HIV infection are at increased risk for the progression of atherosclerosis7 as well 
as infectious diseases such as tuberculosis (TB).8 This review postulates that the 
compromise in macrophage function that occurs with HIV may increase the risk of 
both atherosclerosis as well as susceptibility to Mycobacterium tuberculosis (M. tb) 
infection. The increase in ox-LDL ingestion and resulting macrophage dysfunction 
may contribute to the increased risk for M. tb infection in both HIV-positive and 
HIV-negative individuals.
Atherosclerosis
Atherosclerosis is a leading cause of coronary heart disease and stroke, which were 
responsible for more than 589,000 deaths in 2005 – almost 25% of all deaths in the 
United States. Each year more than 1.2 million will suffer a coronary attack and almost HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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800,000 people will suffer a stroke. Atherosclerosis is a 
process in which deposits of fatty substances, cholesterol, 
cellular waste products, calcium and other substances build 
up in the inner lining of an artery. This build-up is called 
plaque.7 It usually affects large- and medium-sized arteries. 
Some hardening of arteries often occurs when people grow 
older. Plaques can grow large enough to significantly reduce 
the blood’s flow through an artery. But most of the damage 
occurs when they become fragile and rupture. Plaques that 
rupture cause blood clots to form that can block blood flow 
or break off and travel to another part of the body. If either 
happens and blocks a blood vessel that feeds the heart, it 
causes a heart attack. And if blood supply to the arms or legs 
is reduced, it can cause difficulty walking and eventually 
lead to gangrene. Atherosclerosis can result in myocardial 
infarction, and bits of plaque can lodge in arteries in the 
brain, causing a stroke.7
Glutathione
GSH is a tripeptide that, in its reduced form, protects cells 
against oxidizing agents, free radicals and reactive oxygen 
intermediates (ROI). In addition to its antioxidant role, 
GSH plays a vital role in maintenance of cell viability 
and   regulating immune cell functions.9 Synthesis of GSH 
occurs in 2 steps. The initial step (the rate limiting step) is 
the   formation of a dipeptide, γ-glutamyl cysteine, a   reaction 
that is catalyzed by γ-glutamylcysteine synthetase. Intracel-
lular levels of L-cysteine are substantially lower than levels 
of L-glutamate and glycine. Therefore, GSH synthesis 
is limited by the availability of cysteine.10 The second 
step involved in the synthesis of GSH is the formation of 
γ-glutamyl cysteine glycine, catalyzed by the enzyme GSH 
synthetase.10 Intracellular GSH levels can be increased or 
decreased by treatment with N-acetyl cysteine (NAC) or 
buthionine sulfoximine (BSO), respectively. The most effi-
cient way to increase the levels of cysteine in cells grown 
in vitro is to supply the culture medium with NAC, which 
is easily taken up by the cells and is nontoxic. Intracel-
lularly, NAC is de-acetylated and cysteine is utilized for 
GSH synthesis. BSO specifically inhibits the activity of the 
γ-glutamyl-cysteinyl synthetase enzyme, which catalyzes 
the first step reaction in the synthesis of GSH,9,10 leading to 
inhibition in the synthesis of GSH.
Oxidized LDL
Oxidation of LDL (ox-LDL) cholesterol has been shown 
to convert LDL cholesterol to a form that is recognized by 
scavenger receptors on macrophages and to contribute to 
foam cell formation.6 It has been known for some time that 
vitamin E and β-carotene are found in the LDL   complex 
and that decreases in vitamin E and β-carotene are early 
events reflecting the initial stages of lipid   peroxidation for-
mation.11 It has only recently been shown that   glutathione 
peroxidase (GPx) is also found to occur naturally in the 
LDL lipoprotein. Substituting the unique substrate for 
GPx, reduced GSH, with liposomal GSH can slow the 
formation of ox-LDL in vitro in human blood and slow 
atherosclerosis in vivo in the ApoE(−/−) mouse model of 
atherosclerosis.12
Ox-LDL and atherosclerosis
Ox-LDL has been shown in several studies to be an inde-
pendent marker of the progression of atherosclerosis.1–4 The 
pathophysiology relates to macrophage ingestion of excess 
ox-LDL and the formation of foam cells, the acknowledged 
trigger of atherosclerosis.5 The mechanism of ox-LDL 
and the requirement for GSH to prevent oxidation of LDL 
cholesterol has been described in Rosenblat et al12 using 
liposomal GSH as the source of GSH in both human blood, 
in vitro studies and in the mouse model of atherosclerosis. 
This study demonstrated that both LDL and HDL contain 
the antioxidant enzyme GSH peroxidase embedded in the 
lipoprotein.12 As GSH is the single substrate for GSH 
peroxidase, a continuous supply of GSH in the reduced 
state is needed to prevent the oxidation of LDL and HDL 
cholesterol. This study also demonstrated that preventing 
the oxidation of LDL and increasing the intracellular GSH 
levels is able to maintain normal macrophage function. It 
is likely that the presence of excess amounts of ox-LDL 
will be an indicator of general macrophage dysfunctions as 
it has been shown to stimulate the release of macrophage 
inflammatory protein 1-alpha (MIP-1alpha)5 as well as other 
immune responses. Ox-LDL is known to be ingested by 
macrophages and without adequate antioxidant function is 
prone to form foam cells (Figure 1), a transition which is 
also a contributing factor to the formation of atherosclerosis14 
and atherosclerotic lesions.13–15
Macrophages and atherosclerosis
Macrophages are derived from the circulating pool of mono-
cytes.16 Monocytes are produced in the bone marrow and, 
in the absence of specific survival signals, are programmed 
to undergo apoptosis in 24–48 hours.16,17 When monocytes 
are recruited into local environments they differentiate into 
macrophages. In arteries, macrophage scavenging function 
may be diverted to the formation of plaque; in the lung HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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they become alveolar macrophages. In atherosclerosis, 
  macrophage oxidative impairment occurs in the GSH-related 
antioxidant system,5 probably related to the unregulated 
ingestion of ox-LDL via the CD36 receptor.18,19
Role of GSH in macrophage 
function
In the natural state, GSH levels are maintained by both the 
synthesis of GSH and by GSH reductase, an enzyme that 
catalyzes the reduction of glutathione disulfide (GSSG) to 
GSH, with NADPH as the reducing cofactor. Increasing the 
expression of GSH reductase, the enzyme which returns GSH 
to the biochemically reduced (functional) state, decreases 
atherosclerotic lesions.20 It has been shown that lymphocyte 
proliferation after mitogenic lectin exposure is decreased21 
with low intracellular GSH.21,22
The level of reduced GSH in the extracellular lung fluid 
(ELF) or alveolar lining fluid has been estimated to be as 
much as 140-fold higher than the level of reduced GSH 
found in the plasma of the same individuals.23 The antioxidant 
GSH is essential for the detoxification of endogenous and 
exogenous oxidant radicals and protection of cells residing 
in the airway and alveolus24,25 and during oxidative stress 
such as cigarette smoking.26 In disease states, the level of 
ELF GSH may decrease dramatically to the point that acute 
respiratory distress syndrome has only 0.05% of the amount 
found in the normal ELF.27
In the lung, intracellular antioxidants are expressed at 
a relatively low level in the lung epithelial tissue and are 
not induced by oxidative stress. The major antioxidants in 
the lung are extracellular and the GSH system is the major 
antioxidant mechanism used in the airways.28 Alveolar 
  macrophage cells rely on the ELF level of GSH to provide 
the biochemical support to maintain intracellular GSH 
levels29 and protect their membranes during the respiratory 
burst.30
When macrophage GSH availability is limited,   cellular 
functions such as phagocytosis and microbial clearance are 
compromised.24 The mouse model of decreased   alveolar 
macrophage GSH resulted in a decrease in the rate of phago-
cytosis of individual macrophages as well as a decrease 
in the overall percentage of macrophages positive for 
  phagocytosis.24 Similar findings have been reported in the 
alveolar function of guinea pigs exposed to ethanol in utero 
  resulting in low macrophage GSH. The addition of precursors 
of GSH to the diet of the ethanol-exposed animals increased 
the GSH levels in the ELF and alveolar macrophages and 
maintained both the rate of internalization and the number 
of macrophages positive for internalization.24 It was also 
shown that decreased GSH availability in the ELF and 
alveolar macrophages of ethanol-fed mice resulted in an 
increase of apoptosis of macrophages that could be reversed 
by   maintaining GSH availability.24
GSH and arterial macrophage 
functions in atherosclerosis
GSH deficiency in the macrophage has been shown to be 
associated with compromise of mitochondrial function. GSH 
plays an integral role in protecting the mitochondria from ROI 
damage and it is the level of mitochondrial GSH that deter-
mines when cellular toxicity commences.18 GSH deficiency 
in mitochondria contributes to macrophage   dysfunction in 
atherosclerosis. Data from a study of the upregulation of 
GSH reductase in macrophages provide direct evidence that 
the GSH-dependent anti-oxidant system in macrophages 
plays a critical role in atherogenesis.20 The study shows that 
overexpression of GSH in either   mitochondria or the cytosol 
of macrophages decreases the severity of atherosclerosis in 
this animal model.20
Ox-LDL-related peroxyl radical formation is implicated 
in both mitochondrial dysfunction and macrophage lysis.19 
Ox-LDL toxicity is related to compromise of   mitochondrial 
function including an increase in mitochondrial Ca+2, 
  opening of mitochondrial permeability transition pores and 
  depolarization of mitochondrial membrane potential.
Foam cell
CD36 mediated
internalization Oxidized LDL
Figure  1  Receptor  mediated  uptake  of  oxidized  low  density  lipoproteins  by 
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It has been observed that maintaining adequate GSH 
levels in macrophage will prevent the toxicity of ox-LDL 
in an in vitro macrophage model.31–33 These findings help 
explain why a decreased amount of reduced GSH in blood 
has been shown to be an independent marker of progression 
of atherosclerosis in 2 studies.13,14
HIV
Worldwide, it is estimated that approximately 40 million 
people are infected with HIV, two-thirds of whom live in 
sub-Saharan Africa. Three regions, Africa, Asia, and Latin 
America, have the highest rates of new infections. AIDS 
is the fourth leading cause of death worldwide.34 HIV is 
the cause of AIDS. Both HIV-1 and HIV-2 cause AIDS, 
but HIV-1 is found worldwide, whereas HIV-2 is found 
  primarily in West Africa. HIV preferentially infects and kills 
CD4+ T lymphocytes, resulting in the loss of cell-mediated 
immunity and a high probability that the host will develop 
opportunistic infections. HIV-infected individuals have an 
increased risk for atherosclerosis and susceptibility to M. tb 
infection.35
HIV and atherosclerosis
As people with HIV live longer due to effective   combination 
antiretroviral therapy (ART), cardiovascular disease has 
become an increasingly important cause of morbidity and 
mortality. But it remains controversial whether HIV   infection 
contributes to accelerated atherosclerosis independent of 
traditional cardiovascular risk factors. In a recent cross-
sectional study, more than 400 HIV-positive participants 
without pre-existing cardiovascular disease in the FRAM 
(Fat Redistribution and Metabolic Change in HIV Infection) 
study were compared with HIV-negative participants in the 
MESA (Multi-Ethnic Study of Atherosclerosis) cohort.7 
The preclinical atherosclerosis was assessed by measuring 
carotid intima-media thickness (IMT), or thickness of the 
walls of the arteries in the neck that supply the brain. IMT 
was   evaluated at 2 sites in the artery, known as the internal/
bulb. Even after adjustment for traditional cardiovascular 
disease risk factors, HIV infection was accompanied by 
more extensive atherosclerosis as measured by IMT.7 The 
association of HIV   infection with IMT was similar to that 
of traditional   cardiovascular disease risk factors, such 
as   smoking. The impact of HIV infection on preclinical 
atherosclerosis overrides any small differences related to 
antiretroviral therapy or specific drug classes. The effect of 
HIV is so big that no drug or class of drugs stands out as 
being an effective contributor.7
GSH and HIV-infection
Findings from our research laboratory as well as by other 
groups confirm that intracellular levels of GSH are decreased 
in patients with AIDS,35 in whom the risk of TB is many times 
that of healthy individuals.35 The factors responsible for low 
GSH in HIV infection are poorly understood. Infection with 
HIV is believed to trigger a range of metabolic changes in 
addition to the progressive deficits in cellular immunity and 
increased susceptibility to opportunistic infections that are 
its clinical hallmarks, and the progression to AIDS.36–45 The 
decreased GSH content in immune cells of HIV-positive 
individuals was at least in part attributed to the decrease in 
plasma cysteine and increased plasma glutamate (an   inhibitor 
of cysteine permeation via the Xc-transport system), as 
observed during early infection (Figure 2). The decreased 
intracellular GSH and plasma cysteine observed in HIV 
patients may also be due to chronic oxidative stress and this 
may lead to the progression of the disease. The decreased 
availability of cysteine can be overcome to some extent by the 
cysteine precursor NAC.42 Herzenberg and colleagues found 
that NAC treatment improves the clinical situation and delays 
y-glutamylcysteine synthase
Impaired cysteine transport
Membrane damage
Cysteine
TNF-Alpha
ROI
GSSH
GSH
NADPH oxidase
Figure  2  Possible  causes  for  decreased  intracellular  levels  of  glutathione  in 
individuals with HIV and/or M. tb infection.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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the disease progression.43 This study showed that long-term 
NAC administration to AIDS patients improves their hema-
tological profile, GSH content and life expectancy.43
Ox-LDL and HIV
Increased incidence of cardiovascular events in HIV 
patients has sparked interest in elucidating the molecular 
mechanism behind endothelial dysfunction resulting in 
atherosclerotic pathology. While there is no evidence within 
the   literature of a molecular mechanism responsible for 
increased   cardiovascular risk within such HIV+ cohorts, 
animal   models expressing transgenic HIV-1 offer a promising 
insight. One such study has shown significantly increased 
aortic arch   lectin-like oxidized-low-density-lipoprotein 
receptor-1 (LOX-1) gene expression in HIV-1 transgenic 
rats compared to control rats.46 LOX-1 is an endothelial 
receptor for ox-LDL and is hypothesized to be an early 
marker of endothelial   dysfunction. It has been proposed that 
endothelial   dysfunction is the first step in progression towards 
atherosclerotic plaque   formation. This same group has also 
  demonstrated   significantly increased expression of inflamma-
tory endothelial adhesion   molecules in the same HIV-1 model. 
Both inducible   vascular cell   adhesion   molecule-1 (VCAM-1) 
and constitutively expressed   intercellular adhesion 
  molecule-1 (ICAM-1) were both significantly elevated in 
HIV-1 transgenic rats compared to control rats, strongly   
suggesting for the first time that the HIV infection, inde-
pendent of antiretroviral   therapy-associated   dyslipidemia, 
is capable of pathologic endothelial   dysfunction that may 
prelude   atherosclerotic plaque formation in major blood   
vessels.46
Tuberculosis
TB is the most prevalent infectious disease in the   world.47–54 
In recent years there has been a significant increase in the 
incidence of TB due to the emergence of multi-drug resis-
tant strains of M. tb and the increased numbers of highly 
susceptible immuno-compromised individuals arising from 
the AIDS pandemic.8 It is also believed that in developing 
countries, as many as 40%–80% of individuals with AIDS 
are at risk of developing TB.8,35 The innate and adaptive 
immune systems contribute to host defenses against M. tb 
infection.48–54 Control of M. tb infection occurs both at the 
macroscopic and cellular levels. At the macroscopic level, 
the physical containment of viable mycobacteria within 
fibrotic granulomas contributes to prevention of overt 
  disease.49–50 Control of mycobacterial replication also occurs 
within   macrophages. Resident tissue macrophages provide 
the first-line defense against M. tb infection. Macrophages 
and natural killer (NK) cells play an important role in innate 
defense against M. tb infection.51–53
Tuberculosis and GSH
Our group reported that GSH plays a key role in limiting 
intracellular growth of Mycobacterium bovis BCG in nitric 
oxide (NO)-deficient macrophages, such as macrophages 
derived from inducible nitric oxide synthase (NOS2)-knock 
out mice and human peripheral blood monocyte-derived mac-
rophages (HMDM). Thus, GSH has direct antimycobacterial 
activity distinct from its role as an NO carrier, functioning 
as an effector molecule in innate defense against M. tb 
infection.47,51,52 These results unfold a novel and potentially 
important innate defense mechanism adopted by human 
macrophages to control M. tb infection.51,52 Consistent with 
these observations, we have also found that GSH mediates 
growth control of virulent M. tb in human blood cultures.35,53 
These results indicate that the inability of immune cells to 
contain M. tb growth may be a consequence of the inability 
of the immune cells to maintain adequate GSH levels during 
in vitro infection.35 Furthermore, our recent studies indicate 
that GSH in combination with cytokines such as interleukin 
(IL-2) and IL-12, activate NK cells to control M. tb infec-
tion.53 Most importantly, our recent studies demonstrate 
that GSH levels are significantly reduced in peripheral 
blood mononuclear cells and red blood cells isolated from 
TB patients and this decrease correlates with increased pro-
inflammatory cytokine production and enhanced growth of 
M. tb.54 Our group was the first to report that GSH levels are 
decreased in individuals with pulmonary TB and to correlate 
GSH levels with protective immunity.54 Furthermore, our 
study provides a direct relationship between decreased GSH 
levels, pro-inflammatory cytokine production and enhanced 
growth of M. tb in TB patients.54
ROI, GSH and TB
ROI are generated from NADPH through a catalytic reac-
tion of membrane bound enzyme NADPH oxidase, which 
is activated by assembling cytosolic regulatory components. 
The most important characteristic of ROI, either in vivo or in 
vitro, is peroxidation of lipids resulting in tissue damage and 
death of affected cells. Lipid peroxidation is a chain reaction 
providing a continuous supply of free radicals that initiate 
further peroxidation.55 Free radical-induced lipid peroxida-
tion causes marked alterations in the structural integrity 
and functions of membrane. The lipid peroxides formed at 
the primary site such as lungs could be transferred through HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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the circulation to other organs and tissues.56–58 Jack et al59 
reported that several circulating markers of free radical 
activity were increased in pulmonary TB patients and some 
of these markers remain elevated even after completion of 
antimicrobial chemotherapy, indicating ongoing oxidative 
stress, which may contribute to decreased GSH levels. It 
is our prediction that in active TB, increased levels of ROI 
cause impaired cystine transport leading to decreased levels 
of GSH (Figure 2).
TNF-α, ROI and GSH
It has been shown that TNF-α stimulates ROI production. 
TNF-α could impair GSH-redox status by production of 
ROI, and impairment of the GSH-reductase system, thereby 
leading to decreased regeneration of reduced GSH from 
oxidized GSSG (Figure 2). Moreover, enhanced ROI is 
likely to increase TNF-α in various cells, and depletion of 
reduced GSH will increase the inflammatory response to the 
cytokine. Nuclear factor-kappa B (NF-κB) is a DNA binding 
protein and a ROI-sensitive transcription factor for several 
cytokines, including TNF-α.57 While NF-kB activation 
(leading to TNF-α production) is induced and enhanced by 
ROI, it can also be blocked by anti-oxidants such as vitamin 
E and GSH-enhancing agents such as NAC.57 Excessive 
production of TNF-α and increased tissue sensitivity to this 
cytokine has been implicated in the immunopathology of TB, 
such as caseous necrotizing reactions. For example, excess 
TNF-α (relative to its receptors) in human bronchoalveolar 
lavage fluid was associated with tissue necrosis and cavity 
formation.59–61 Systemic spillover of TNF-α may account 
for unwanted inflammatory effects like fever and wasting, 
which manifests clinically as cachexia, consistent with the 
original designation as cachetin.65 In HIV-infected persons, 
the effects of TNF-α may be particularly deleterious, as this 
cytokine has been implicated as a stimulus for HIV expres-
sion and for activation-induced T cell apoptosis. For these 
reasons, several studies have examined anti-TNF treatments 
in persons with AIDS and in HIV+ TB.62–65 Thus enhanced 
TNF-α production may represent a pathogenic loop, leading 
to enhanced inflammation and ROI production, leading to 
reduced GSH levels.
Atherosclerosis and tuberculosis
Atherosclerosis is an inflammatory disease involving the 
accumulation of macrophages in the intima. Wnt5a is a nonca-
nonical member of the Wnt family of secreted glycoproteins. 
Recently, human macrophages have been shown to express 
Wnt5a upon stimulation with bacterial pathogens in vitro 
and in granulomatous lesions in the lung of M. tb-infected 
patients. Wnt5a expression has also been linked to Toll-like 
receptor-4 (TLR-4), an innate immune receptor implicated 
in atherosclerosis. These observations, along with the fact 
that Wnt5a is involved in cell migration and proliferation, 
led Christman et al to postulate that Wnt5a plays a role in 
atherosclerosis.66 To investigate this hypothesis, Christman 
et al characterized Wnt5a expression in murine and human 
atherosclerotic lesions. Tissue sections derived from the aortic 
sinus to the aortic arch of apolipoprotein E-deficient mice and 
sections derived from the carotid arteries of patients undergo-
ing endarterectomy were subjected to immunohistochemical 
analysis. All samples were found to be positive for Wnt5a with 
predominant staining in the areas of macrophage accumula-
tion within the intima. In parallel, the investigators probed 
for the presence of TLR-4 and found coincident TLR-4 and 
Wnt5a expression.66 For both the Wnt5a and TLR-4 stain-
ing, consecutive tissue sections treated with an isotype- and 
species-matched Ig served as a negative control and exhibited 
little, if any, reactivity. Quantitative RT-PCR revealed that 
Wnt5a mRNA expression in RAW264.7 murine macrophages 
can be induced by stimulation with LPS, a known ligand for 
TLR-4. Combined, these findings demonstrate for the first 
time Wnt5a expression in human and murine atherosclerotic 
lesions and suggest that cross-talk between TLR-4 and Wnt5a 
is operative in atherosclerosis.66
Conclusion
Macrophage functions are compromised by decreased intracel-
lular levels of GSH when an excess of ox-LDL is present. This 
has been shown to increase the development and progression 
of atherosclerosis. Reduction of intracellular GSH is a feature 
of HIV , which is also associated with an increased risk of 
atherosclerosis. The compromise of innate immune function 
that occurs with low GSH in the macrophage may also increase 
susceptibility to infection with M. tb, for which individuals with 
HIV have an increased risk. It is possible that the compromise 
of macrophage function related to the ingestion of ox-LDL and 
the decreased macrophage levels of GSH increase the risk of 
contracting macrophage-related infectious disease such as M. 
tb infection in both HIV-positive and HIV-negative individuals. 
These observations suggest that further investigation into the 
relationship between low GSH, increased ox-LDL and suscep-
tibility to infection with M. tb is warranted.
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